MGMTP140K retroviral vector

MGMTP140K retroviral vector is a gene therapy vector designed to express a mutant form of the O6-methylguanine-DNA methyltransferase (MGMT) enzyme. This P140K mutant version of MGMT provides resistance to O6-benzylguanine (O6BG), which is an inhibitor of wild-type MGMT, while maintaining its ability to repair DNA damage caused by alkylating agents[1][2]. ## Mechanism of Action MGMTP140K retroviral vector works by introducing the mutant MGMT gene into hematopoietic stem cells (HSCs). When these modified cells are reinfused into patients, they gain resistance to the combination of O6BG and alkylating agents like temozolomide (TMZ) or BCNU (carmustine)[5][7]. This allows for in vivo selection and expansion of gene-modified cells after chemotherapy, as unmodified cells are killed by the treatment while modified cells survive[7][8]. The vector is designed to protect HSCs from the myelosuppressive toxicity that typically occurs with alkylating agent chemotherapy. Since MGMT detoxifies O6-alkylguanine adducts in a stoichiometric manner, the level of MGMT expression is crucial for protection[1]. However, research has shown that very high expression of MGMTP140K can paradoxically impair protection and cellular proliferation[1][2]. ## Clinical Applications MGMTP140K retroviral vector has been studied in clinical trials for various applications: 1. Protection of hematopoietic stem cells during chemotherapy for solid tumors[6] 2. Treatment of genetic diseases where in vivo selection of gene-modified cells is beneficial 3. Potential application in HIV/AIDS gene therapy when combined with anti-HIV transgenes[8] The vector has been incorporated into different viral delivery systems, including gamma-retroviral vectors, lentiviral vectors, and foamy virus vectors, each with specific advantages for different applications[7][8]. ## Development Status Clinical trials using MGMTP140K-modified cells have been conducted for various conditions. A Phase I clinical trial using retroviral gene transfer of a similar MGMT mutant (G156A) for advanced solid tumors has been completed[6]. More recently, a Phase II trial studying P140K MGMT hematopoietic stem cells with O6-benzylguanine, temozolomide, and carmustine has been initiated[10]. The technology has shown promising results in preclinical models, including efficient and stable selection of long-term repopulating stem cells in nonhuman primates[5][7].

Other names

P140K mutant O6-methylguanine-DNA methyltransferase retroviral vectorP-140K mutant O6-methylguanine-DNA methyltransferase retroviral vectorP 140K mutant O6-methylguanine-DNA methyltransferase retroviral vectorMGMT(P140K) retroviral vector